EV-301 long-term outcomes: 24-month findings from the phase III trial of enfortumab vedotin versus chemotherapy in patients with previously treated advanced urothelial carcinoma☆
Titel:
EV-301 long-term outcomes: 24-month findings from the phase III trial of enfortumab vedotin versus chemotherapy in patients with previously treated advanced urothelial carcinoma☆
Auteur:
Rosenberg, J.E. Powles, T. Sonpavde, G.P. Loriot, Y. Duran, I. Lee, J.-L. Matsubara, N. Vulsteke, C. Castellano, D. Mamtani, R. Wu, C. Matsangou, M. Campbell, M. Petrylak, D.P.